Compare FORM & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORM | CORT |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.7B |
| IPO Year | 2002 | 2001 |
| Metric | FORM | CORT |
|---|---|---|
| Price | $106.48 | $87.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $152.22 | $141.00 |
| AVG Volume (30 Days) | ★ 1.8M | 770.3K |
| Earning Date | 10-28-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.96 | 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $31.70 | $50.53 |
| Revenue Next Year | $18.42 | $46.23 |
| P/E Ratio | ★ $105.15 | $970.17 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $44.16 | $28.66 |
| 52 Week High | $160.27 | $126.38 |
| Indicator | FORM | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 25.54 |
| Support Level | $100.56 | $77.38 |
| Resistance Level | $157.08 | $122.93 |
| Average True Range (ATR) | 6.63 | 5.88 |
| MACD | -3.20 | -3.63 |
| Stochastic Oscillator | 27.26 | 8.45 |
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.